Cubist Systematic Strategies LLC grew its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 229.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 36,285 shares of the pharmaceutical company’s stock after purchasing an additional 25,285 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in GlaxoSmithKline were worth $1,473,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. 1st Global Advisors Inc. raised its holdings in GlaxoSmithKline by 0.4% during the 2nd quarter. 1st Global Advisors Inc. now owns 5,271 shares of the pharmaceutical company’s stock worth $227,000 after purchasing an additional 19 shares during the last quarter. King Luther Capital Management Corp increased its stake in shares of GlaxoSmithKline by 1.0% in the 2nd quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock valued at $234,000 after acquiring an additional 55 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its stake in shares of GlaxoSmithKline by 1.9% in the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock valued at $137,000 after acquiring an additional 64 shares in the last quarter. Strategic Global Advisors LLC increased its stake in shares of GlaxoSmithKline by 0.6% in the 2nd quarter. Strategic Global Advisors LLC now owns 12,179 shares of the pharmaceutical company’s stock valued at $525,000 after acquiring an additional 75 shares in the last quarter. Finally, PagnatoKarp Partners LLC increased its stake in shares of GlaxoSmithKline by 1.4% in the 2nd quarter. PagnatoKarp Partners LLC now owns 5,812 shares of the pharmaceutical company’s stock valued at $253,000 after acquiring an additional 80 shares in the last quarter. Hedge funds and other institutional investors own 9.83% of the company’s stock.

Shares of GlaxoSmithKline plc (GSK) opened at $34.99 on Friday. The company has a market cap of $86,052.55, a price-to-earnings ratio of 12.41, a price-to-earnings-growth ratio of 1.94 and a beta of 0.98. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64. GlaxoSmithKline plc has a one year low of $34.52 and a one year high of $44.53.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Shareholders of record on Friday, November 10th will be paid a dividend of $0.5037 per share. This represents a $2.01 dividend on an annualized basis and a yield of 5.76%. The ex-dividend date is Thursday, November 9th. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. GlaxoSmithKline’s payout ratio is 163.12%.

GSK has been the subject of several research analyst reports. BidaskClub upgraded shares of GlaxoSmithKline from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Argus reiterated a “buy” rating and issued a $50.00 price objective on shares of GlaxoSmithKline in a research note on Thursday, August 31st. Morgan Stanley lowered shares of GlaxoSmithKline from an “equal weight” rating to an “underweight” rating in a research note on Friday, September 8th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Thursday, September 14th. Finally, Zacks Investment Research upgraded shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research note on Wednesday, October 18th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $39.37.

In other news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the business’s stock in a transaction on Monday, November 6th. The shares were purchased at an average cost of $14.00 per share, with a total value of $5,999,994.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 10.00% of the stock is owned by insiders.

WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/17/cubist-systematic-strategies-llc-has-1-47-million-holdings-in-glaxosmithkline-plc-gsk.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related stocks with our FREE daily email newsletter.